Niklas speaks with Zina Sarif, the Founder and Managing Director of Yendou, a company on a mission to accelerate clinical research and make it universally accessible to patients, clinicians, and scientists.
Zina starts by talking about her familial experiences with cancer during her upbringing in Morocco, and how it motivated her to dedicate her life to combating cancer.
During her career as.a cancer scientist in Germany, Zina experienced the inefficiencies and bureaucratic obstacles to bringing solutions from the science to market.
It takes 12 years and $800m in cost to bring a new treatment to market, and the shortened patent life cycle pushes for non-patient-centric incentives.
"We are currently not winning the war against cancer," so Zina.
However, Zina has identified hope for patients.
Clinical trials contain the most innovative treatments for cancer, and they typically take place in large hospitals with great infrastructure and care options for patients,
Yet only 8% of cancer patients globally are participating in clinical trials, and it takes 18 months to get access - often too long to have a chance at survival
With Yendou, Zina aims to reduce the time to access new treatments from 18 to 4 months and enable more patients to access them.
But this is only the beginning. Long-term, Yendou aims to reduce the time for clinical trials from 12 to 7 years and reduce costs from $800m to $300m.
We learn in the conversation how medical innovation in oncology is held back by a Kafkaesque bureaucracy, a frustrating reality that takes a toll on innovators.
Yet, Zina is bent on overcoming seemingly insurmountable obstacles and encouraging hope that the war against cancer is not over.
Niklas on Twitter: https://twitter.com/NiklasAnzinger
Infinita Fund Website: https://infinitafund.com/
Discord: https://discord.gg/Z4H6UjbubK
View all episodes
By Infinita City
5
44 ratings
Niklas speaks with Zina Sarif, the Founder and Managing Director of Yendou, a company on a mission to accelerate clinical research and make it universally accessible to patients, clinicians, and scientists.
Zina starts by talking about her familial experiences with cancer during her upbringing in Morocco, and how it motivated her to dedicate her life to combating cancer.
During her career as.a cancer scientist in Germany, Zina experienced the inefficiencies and bureaucratic obstacles to bringing solutions from the science to market.
It takes 12 years and $800m in cost to bring a new treatment to market, and the shortened patent life cycle pushes for non-patient-centric incentives.
"We are currently not winning the war against cancer," so Zina.
However, Zina has identified hope for patients.
Clinical trials contain the most innovative treatments for cancer, and they typically take place in large hospitals with great infrastructure and care options for patients,
Yet only 8% of cancer patients globally are participating in clinical trials, and it takes 18 months to get access - often too long to have a chance at survival
With Yendou, Zina aims to reduce the time to access new treatments from 18 to 4 months and enable more patients to access them.
But this is only the beginning. Long-term, Yendou aims to reduce the time for clinical trials from 12 to 7 years and reduce costs from $800m to $300m.
We learn in the conversation how medical innovation in oncology is held back by a Kafkaesque bureaucracy, a frustrating reality that takes a toll on innovators.
Yet, Zina is bent on overcoming seemingly insurmountable obstacles and encouraging hope that the war against cancer is not over.
Niklas on Twitter: https://twitter.com/NiklasAnzinger
Infinita Fund Website: https://infinitafund.com/
Discord: https://discord.gg/Z4H6UjbubK
226,206 Listeners
16,101 Listeners
2,395 Listeners
1,784 Listeners
2,316 Listeners
269 Listeners
7,087 Listeners
1,404 Listeners
9,170 Listeners
408 Listeners
15,237 Listeners
91 Listeners
94 Listeners
125 Listeners
145 Listeners